Get To Know Us

Our Expertise

Guided by category pioneers and inventors of this technology as well as seasoned entrepreneurs, we are rigorously pursuing our mission to improve outcomes for individuals affected by challenging chronic respiratory diseases.

Our Team

Dave Richards

David Richards

Chief Executive Officer

Board Member

Learn More
Veronica L. Hall, Ph.D.

Veronica L. Hall, Ph.D.

Chief Development Officer, Head of R&D

Learn More
Charles McOsker, Ph.D.

Charles McOsker, Ph.D.

Co-founder & Chief Scientific Officer

Learn More
Thomas Hofmann, M.D., Ph.D.

Thomas Hofmann, M.D., Ph.D.

Chief Medical Officer (acting)

Learn More
Steve St. Onge, PharmD, MBA

Steve St. Onge, PharmD, MBA

Chief Business Officer

Learn More
George Arida

George Arida

Chief Financial Officer (acting)

Learn More
Brendan Doran, PharmD

Brendan Doran, PharmD

Chief Operating Officer

Learn More
James Rogers, Ph.D.

James Rogers, Ph.D.

Executive Director, Project Operations

Learn More
Dayna Schwartz, M.D., MS

Dayna Schwartz, M.D., MS

Director of Clinical Development and Portfolio Strategy

Learn More
Gaby Baldeon Vaca, Ph.D.

Gaby Baldeon Vaca, Ph.D.

Principal Scientist

Learn More
Robin Joy Edmonds

Robin Joy Edmonds

Manager, Project Operations

Learn More

Board of Directors

Peter G. Kleinhenz

Peter G. Kleinhenz

Co-founder & Board Chair

Learn More
Michael Triplett, Ph.D.

Michael Triplett, Ph.D.

Co-founder & Board Member

Learn More
Bill Baumel

Bill Baumel

Board Member

Learn More
Chuck Bramlage

Chuck Bramlage

Board Member

Learn More
Larry Edwards

Larry Edwards

Board Member

Learn More
Dave Richards

David Richards

Chief Executive Officer

Board Member

Learn More
Douglas Thomson

Douglas Thomson

Board Member

Learn More
Wayne Embree

Wayne Embree

Board Observer

Learn More
Faith Voinovich

Faith Voinovich

Board Observer

Learn More

Scientific Advisors

Jeffrey Almond, Ph.D.

Jeffrey Almond, Ph.D.

Scientific Advisory Board Member

Learn More
Bruce Forest, M.D.

Bruce Forest, M.D.

Scientific Advisory Board Member

Learn More
Palani Palaniappan, Ph.D.

Palani Palaniappan, Ph.D.

Scientific Advisory Board Member

Learn More
Obadiah Plante, Ph.D.

Obadiah Plante, Ph.D.

Scientific Advisory Board Member

Learn More
Brian Price, Ph.D.

Brian Price, Ph.D.

Scientific Advisory Board Member

Learn More
George Siber, M.D.

George Siber, M.D.

Scientific Advisory Board Member

Learn More
David Zarley, Ph.D.

David Zarley, Ph.D.

Scientific Advisory Board Member

Learn More

Scientific Founders

Lauren O. Bakaletz, Ph.D.

Lauren O. Bakaletz, Ph.D.

Scientific Co-founder

Learn More
Steven D. Goodman, Ph.D.

Steven D. Goodman, Ph.D.

Scientific Co-founder

Learn More
Juliana Woda, Ph.D.

Juliana Woda, Ph.D.

Scientific Co-founder

Learn More

Strategic Advisors

Stephen Hoffman, M.D., Ph.D.

Stephen Hoffman, M.D., Ph.D.

Strategic Advisor

Learn More
Paul Westberg, MBA

Paul Westberg, MBA

Strategic Advisor

Learn More
Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.